Object: We are committed to studying the characteristics of energy metabolism in bladder cancer patients, and to investigate the regulation of sulforaphane (SFN) on glucose metabolism in bladder cancer cells. Methods: Real-time PCR was used to detect the gene level of glycolysis key rate-limiting enzymes in bladder tumors, and para-carcinoma tissues as control. We also measured the activity of glycolysis enzymes in patient serum and bladder cancer cells by ELISA. Then we measured microRNAs level by microarray after SFN treatment. GO function and KEGG pathway enrichment analyses were used to gain insights into the biological roles and the potential pathway of different expression microRNAs. Results: Gene expression results showed that the level of PFK-1 was highly increased in tumor tissues. However, there is no significant differential in serum activity of PFK-1 as compared with control group. SFN obviously elevated microRNA expression related to glucose metabolism, including miR-200c, miR-34a and let-7. The activity of HK2, which can be blocked by miR-34a, was strongly inhibited in bladder cancer cells by incubating with 20 μmol/L SFN for 24 h. Furthermore, functional annotation analysis results suggest that miR-200c target genes were mainly enriched in 82 GO terms and 17 pathways (P < 0.05), including mTOR signaling (p = 0.0154) and AMPK signaling (p = 0.0158), which also involved in the regulation of energy metabolism. Conclusion: Aberrant gene expression of PFK-1 is one of most important causes of glucose metabolic disorders in bladder cancer patients. SFN can significantly down-regulate glucose metabolism in bladder cancer cells by regulating the expression of glycolysis related-microRNAs.
Citation Format: Yujuan Shan, Lei Huang. Profile of glucose metabolism in bladder cancer patients and the inhibitory effect of sulforaphane on bladder cancer glycolysis by regulating microRNA expression [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr LB-131.